(Q33855964)

29 July 2017

1 reference

title

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting (English)

1 reference

29 July 2017

1 reference

Hesketh PJ

1

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

18

1 reference

29 July 2017

163-173

1 reference

29 July 2017

2

1 reference

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

29 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Neuropharmacology of emesis induced by anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Control of chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

The biological significance of soluble interleukin-2 receptors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Proposal for classifying the acute emetogenicity of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Ondansetron. Therapeutic use as an antiemetic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Effects of granisetron with doxorubicin or epirubicin on ECG intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

Tropisetron. A review of the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009038248

10.3109/07357900009038248

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10705879